Giorgia Nardo
Overview
Explore the profile of Giorgia Nardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
798
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verze M, Boscolo Bragadin A, Minari R, Pasello G, Perrone F, Scattolin D, et al.
J Liq Biopsy
. 2025 Mar;
4:100143.
PMID: 40027148
Introduction: ctDNA is a useful tool for NGS molecular profiling in advanced NSCLC patients. Its clinical applicability in patients with gene rearrangements is still limited due to a lower detection...
2.
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, et al.
Cancer Res
. 2024 Nov;
84(22):3909.
PMID: 39544086
No abstract available.
3.
Lunardi F, Nardo G, Lazzarini E, Tzorakoleftheraki S, Comacchio G, Fonzi E, et al.
J Pers Med
. 2024 Aug;
14(8).
PMID: 39202030
Chronic Obstructive Pulmonary Disease (COPD) and lung cancer are strictly related. To date, it is unknown if COPD-associated cancers are different from the tumors of non-COPD patients. The main goal...
4.
Dal Maso A, Del Bianco P, Cortiula F, Nardo G, Zulato E, Bonanno L, et al.
J Thorac Dis
. 2022 Oct;
14(9):3364-3375.
PMID: 36245580
Background: About 15% of non-small cell lung cancers (NSCLCs) harbor epidermal growth factor receptor () mutations. Upfront treatment with first and second generation EGFR tyrosine kinase inhibitors (1-2gen TKIs) is...
5.
Zulato E, Del Bianco P, Nardo G, Attili I, Pavan A, Boscolo Bragadin A, et al.
Br J Cancer
. 2022 Sep;
127(11):2034-2042.
PMID: 36175621
Background: Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This...
6.
Zulato E, Tosello V, Nardo G, Bonanno L, Del Bianco P, Indraccolo S
Diagnostics (Basel)
. 2021 Aug;
11(8).
PMID: 34441402
Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities for personalized medicine. In this study, we aim to illustrate the implementation of NGS-based liquid biopsy...
7.
Fasolato S, Ruvoletto M, Nardo G, Rasola A, Sciacovelli M, Zanus G, et al.
Biology (Basel)
. 2021 Apr;
10(5).
PMID: 33922660
Cell proliferation and escape from apoptosis are important pathological features of hepatocellular carcinoma (HCC), one of the tumors with the highest mortality rate worldwide. The aim of the study was...
8.
Pavan A, Boscolo Bragadin A, Calvetti L, Ferro A, Zulato E, Attili I, et al.
Transl Lung Cancer Res
. 2021 Feb;
10(1):202-220.
PMID: 33569305
Background: Characterization of tumor-related genetic alterations is promising for the screening of new predictive markers in non-small cell lung cancer (NSCLC). Aim of the study was to evaluate prognostic and...
9.
Nardo G, Carlet J, Marra L, Bonanno L, Boscolo A, Dal Maso A, et al.
Front Oncol
. 2021 Feb;
10:607840.
PMID: 33520716
Background: Molecular profiling of advanced mutated NSCLC has recently demonstrated the co-existence of multiple genetic alterations. Specifically, co-existing -mutations in NSCLCs have been described, despite their prevalence at progression and...
10.
Cortiula F, Pasello G, Follador A, Nardo G, Polo V, Scquizzato E, et al.
Diagnostics (Basel)
. 2020 Oct;
10(10).
PMID: 32998450
Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of...